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Our aim was to assess clinical utility of 99mTc-EDDA/HYNIC-TOC scintigraphy for evaluation of lung lesions in patients 
with neuroendocrine tumors (NETs). Single photon emission computed tomography (SPECT) of the thorax and whole 
body scintigraphy were performed in 34 patients using 99mTc-EDDA/HYNIC-TOC. Visual assessment was complemented 
by semiquantitative evaluation based on tumor to non-tumor (T/NT) ratio. Clinical, laboratory, and histological ﬁndings
served as the standard for comparison. Enhanced tracer uptake was observed on both SPECT and whole body scintigraphy 
in 29 of 34 patients (88% sensitivity). T/NT ratios were signiﬁcantly higher on SPECT than whole body images (2.96±1.07
vs.1.70±0.43, p<0.01) and did not correlate with NET proliferation index Ki-67 (r= - 0.36, p=0.27). Conclusion: 99mTc-EDDA/
HYNIC-TOC scintigraphy is useful for evaluation of NET tissue in the lungs. SPECT provides better visualization of lung 
lesions than whole body scintigraphy. The intensity of tracer uptake, however, does not relate to the proliferation rate of NETs.
99mTc-EDDA/HYNIC-TOC scintigraphy may be helpful for selecting and monitoring treatment options, particularly when 
radiolabeled somatostatin analogue therapy becomes available. 
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More recently, somatostatin analogue depreotide has been 
labeled with 99mTechnetium (99mTc) and the resulting compound 
(NeoSpect) has been approved by the U.S. Food and Drug Ad-
ministration for evaluation of solitary pulmonary nodules [7]. 
However, high uptake in the liver and bone marrow has been 
reported [2, 7]. Mecke and Behe introduced hydrasinonicoti-
namide (HYNIC) as a bifunctional chelator for 99mTc labeling 
of octreotide and Tyr3-octreotide (TOC) with high eﬃciency
[8]. Decristoforo and co-workers reported favorable clinical 
characteristics of HYNIC when ethylene diamine diacetic 
acid (EDDA) was used as a co-ligand, thereby introducing 
99mTc-EDDA/HYNIC-TOC somatostatin analogue to clinical 
practice [9]. Recent investigations indicated a potential value 
of 99mTc-EDDA/HYNIC-TOC for evaluating malignant tumors 
that express SSTRs, especially subtype 2, but indicated the need 
for further investigations [10, 11]. 
The main purpose of this study was to assess the clinical
utility of 99mTc-EDDA/HYNIC-TOC scintigraphy (single 
Expression of somatostatin receptors (SSTRs) has been 
documented in neuroendocrine tumors (NET) and in small 
cell (SCLC) and some non-small cell lung cancers (NSCLC) 
[1, 2]. These receptors constitute molecular basis for clinical
application of somatostatin analogues, particularly for in-vivo 
localization of lung tumors.
Somatostatin analogues, such as the 123Iodine-labeled octre-
otide [3], have been used in attempt to improve early detection 
of NETs and various cancers in the lungs. Since this compound 
has several drawbacks (e.g., high gastrointestinal activity due 
to liver excretion, short half-life), recent eﬀorts have been
focused on labeling octreotide with 111Indium (111In) using the 
chelate dietilene triamine penta-acetic acid, which resulted in 
111In-pentetreotide [4, 5]. 111In-pentetreotide proved sensitivity 
for detecting NETs and bronchogenic carcinoma, although dif-
ferentiating SCLC from NSCLC was not possible [6]. The use
of 111In-pentetreotide, however, has also substantial drawbacks 
(high cost, suboptimal physical characteristics). 
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photon emission computed tomography-SPECT) and whole 
body imaging for evaluation of lung lesions in patients with 
NETs . Our speciﬁc aims were to 1) determine sensitivity of
99mTc-EDDA/HYNIC-TOC scintigraphy for detecting NETs 
in the lungs, 2) compare tumor to non tumor (T/NT) ratio 
of 99mTc-EDDA/HYNIC-TOC on SPECT and whole body 
scintigraphy in lung lesions, and 3) relate the uptake of 99mTc-
EDDA/HYNIC-TOC by NETs to the tumor proliferation 
index Ki-67.
Patients and methods
Patients were recruited from a sample referred by the 
Institute for Endocrinology for clinical staging or follow-up. 
Thirty-four consecutive patients (18 men, 16 women, mean
age 52 years, range 23-74) with a known or suspected NET 
and lung lesions on chest X-ray or computed tomography-CT 
were included in the study. The diagnosis of NET was based
on clinical symptoms, increased urinary excretion of serotonin 
metabolite 5-hydroxyindolacetic acid (5HIAA), chromogranin 
A, and biopsy or postoperative histology. 
Twenty-one patients underwent surgery after 99mTc-EDDA/
HYNIC-TOC scintigraphy (mean interval 14±6 days). For 
13 of 21 patients, Ki-67 labeling index was derived after im-
munostaining tumor material with MIB-1 antibody. The same
13 patients underwent a follow-up 99mTc-EDDA/HYNIC-TOC 
SPECT and whole body scintigraphy between 6 months and 
one year after surgery. 3 patients received radionuclide therapy
with radiolabeled somatostatin analogues while the remaining 
10 of 34 patients continued with a long-acting somatostatin 
analogue treatment. All patients provided written consent 
prior to the study. 
Imaging protocol. Long-acting cold somatostatin analogue 
treatment was stopped one month before imaging. Patients 
were on laxatives and liquid diet for 2 days before the exami-
nation. 99mTc-EDDA/HYNIC-TOC (740 MBq) was injected 
intravenously. Imaging started 2 hours post-injection. A whole 
body scan was ﬁrst performed followed by SPECT of the tho-
rax. Data were acquired using dual-head Mediso or one-head 
e-cam Siemens gamma camera. A general purpose collimator 
and an image matrix of 512x1024 pixels were used for whole 
body scans. SPECT was acquired in 64 projections (each last-
ing 30 sec) with a matrix size of 128x128 pixels.
Image reconstruction and analysis. Reconstruction of to-
mographic images was performed by the iterative method 
(MOSEM). Whole body and SPECT images were ﬁrst evalu-
ated visually by two experienced nuclear medicine physicians. 
Visual appearance of an increased focal uptake of the tracer 
in the suspected tumor site was considered a positive ﬁnding,
which served for determining sensitivity of 99mTc-EDDA/HYN-
IC-TOC SPECT and whole body imaging (aim 1). Subsequent 
semi-quantitative analysis was limited to cases with positive 
ﬁndings to compare the tumor uptake of 99mTc-EDDA/HYNIC-
TOC to non tumor tissue in NETs on SPECT and whole body 
imaging (aim 2). For that purpose, tumor to non-tumor (T/
NT) ratio was calculated after drawing the region of interest
around the lesion and at the corresponding contralateral area 
on both whole body and SPECT images. T/NT ratio was also 
used to relate the uptake of 99mTc-EDDA/HYNIC-TOC by 
NETs to the tumor proliferation index Ki-67 (aim 3).
Statistical analysis. Statistical program SPSS for Windows 
was used for analysis. Standard statistical formula was used for 
calculating sensitivity of scintigraphy (aim 1). Student’s t-test 
was used to test diﬀerences between T/NT ratios derived from
whole body and SPECT images (aim 2). Pearson’s correlation 
coeﬃcient was calculated to relate T/NT ratio to Ki-67 index
(aim 3). Data are presented as mean ± SD. P value of less than 
0.05 was considered signiﬁcant.
Results
Overall, there were 34 primary or metastatic NETs in the 
lungs (see Table 1 for primary tumor locations). Mean lesion 
size on CT was 2.9±1.2 cm (range 1.4-4.1 cm).
Sensitivity of 99mTc-EDDA/HYNIC-TOC scintigraphy. On 
visual examination, both SPECT and whole body scintigra-
phy identically identiﬁed patients with and without increased
99mTc-EDDA/HYNIC-TOC uptake. Increased focal uptake in 
NETs was found in 29 of 34 patients (true positive ﬁndings-
TP), including 14 primary lung NETs (Fig. 1) and 15 lung 
metastases from NETs of diﬀerent or unknown origin. Five
false negative (FN) results included two cases with low-dif-
ferentiated primary lung NETs, a case with lung metastases 
from a low-diﬀerentiated aggressive NET in the esophagus,
and two cases with NETs of unknown origin. The tumor size
for 5 FN cases is given in Table 2. None of 13 patients who 
underwent surgery showed evidence of increased tracer uptake 
in the lungs on the follow-up SPECT or whole body imaging 
(true negative-TN) (Fig 2). Accordingly, the results indicate 
88% sensitivity of both 99mTc-EDDA/HYNIC-TOC SPECT 
and whole body scintigraphy for detecting lung lesions in 
patients with NETs.
T/NT ratio and correlation with Ki-67 proliferation index. 
The mean T/NT ratio for TP cases (n=29) was signiﬁcantly
(p<0.01) higher on SPECT (2.96±1.07) than whole body im-
ages (1.70±0.43). 
Table 1. Primary locations of neuroendocrine tumors (n=34).
Tumor site Number of patients (n)
Lungs 17
Esophagus 2
Appendix 1
Endocrine pancreas 2
Pituitary gland 2
Thyroid 2
Unknown 8
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Figure 1 a) Enhanced uptake of 99mTc-EDDA/HYNIC-TOC 
on whole body scintigraphy in a patient with NET in the 
right upper lobe (arrows); Ki-67 = 37% b) Solitary pulmo-
nary nodule with soft tissue density in the right upper lobe
on CT, di ameter 2.8cm (dash arrow)
Figure 2  a) Enhanced uptake of 99mTc-EDDA/HYNIC-TOC 
on whole body scintigraphy and SPECT in a patient with 
NET in the right lower lobe, diameter 2.2cm (arrow). b) 
No uptake after surgery. Ki-67= 0%.
Figure 3 a) Whole body scan with 99mTc-EDDA/HYNIC-
TOC shows multifocal lung, bone and liver lesions in 
a patient with low diﬀerentiated NET of unknown origin
(black arrows). b) High uptake in the same metastatic 
sites 96 hours after application of the therapeutical dose
(3.5 GBq) of 90Y-DOTA TATE (“bremsstrahlung images”)( 
dash arrows).
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Ki-67 index was 18±7% (range 0-78%) for 13 patients who 
had tumor material immunostained with MIB-1 antibody 
after surgical removal. Ki-67 index was low (0-20%) for 10
patients who had positive ﬁndings on scintigraphy (TP). Two
of the remaining 3 patients had high Ki-67 index and negative 
SPECT and whole body ﬁndings (FN). The correlation between
T/NT ratio and Ki-67 index was negative and not statistically 
signiﬁcant (r= -0.36, p=0.27, n=11).
Preliminary results of peptide receptor radionuclide therapy. 
Because of high uptake of 99mTc-EDDA/HYNIC-TOC in the 
tumor tissue, and after using all available treatment options
(surgery, somatostatin analogues, α-interferons), three pa-
tients with metastatic NETs underwent a peptide receptor 
radionuclide therapy with 90Yttrium tetraazacyclododecane 
tetra acetic acid (metal chelator-DOTA) Tyr3-octreotate 
(TATE)-90Y DOTA TATE (Fig. 3). At the clinical follow-up 
6 to 12 months later, one patient was in a partial remission, 
one was in a stable condition, and one was presented with 
signs of disease progression.
Discussion
This study has 3 main ﬁndings. First, it demonstrates high
sensitivity of 99mTc-EDDA/HYNIC-TOC scintigraphy for 
detecting tumor tissue within lungs in patients with NETs. 
Secondly, T/NT ratio of 99mTc-EDDA/HYNIC-TOC is expect-
edly higher on SPECT than whole body scintigraphy. Finally, 
the intensity of tracer uptake does not correlate with the rate 
of NET proliferation (Ki-67 index).
The diagnosis of lung tumors remains a challenge. Conven-
tional radiologic imaging techniques are of limited value for 
detecting malignant solitary lung lesions because of 20-50% er-
ror rate [12]. That is not surprising since radiologic assessment
is mainly based on a lesion size or detection of calciﬁcations
[12]. High diagnostic accuracy of contrast-enhanced CT is 
promising but requires further validation [13]. Bronchoscopy 
is only useful when lesion is accessible for a bronchoscope. 
The receptor scintigraphy widens the spectrum of available
methods, particularly in uncertain cases [11]. 
The reported 88% sensitivity of both 99mTc-EDDA/HYNIC-
TOC SPECT and whole body scintigraphy for detecting 
primary lung NETs or lung metastases is in agreement with 
previous reports [14, 15]. Several factors may be responsible 
for our FN ﬁndings, such as an insuﬃcient expression of 
SSTR2 for in-vivo detection by 99mTc-EDDA/HYNIC-TOC 
or a comparably higher expression of other SSTR subtypes 
(SSTR3, SSTR4 or SSTR5) in our cases with low-diﬀerentiated
tumors. Additional reasons may be a limited spatial resolu-
tion of SPECT imaging system along with relatively small 
size of lung lesions in 3 patients (1.4 cm, 1.7 cm and 1.9 cm, 
respectively). Finally, a non-speciﬁc uptake of radiolabeled
somatostatin analogues, such as in arteries supplying tumor 
tissue or in epithelial cells of lung granulomatosis, also needs 
to be considered when interpreting the accumulation of 
99mTc-EDDA/HYNIC-TOC. This factors may inﬂuence the
speciﬁcity of the method [16, 17, 7].
Semiquantitative results in our study conﬁrm previously
reported higher T/NT ratios on SPECT than whole body 
images [9, 15]. As expected, therefore, SPECT should be pre-
ferred over whole body scintigraphy as it can more precisely 
detect and localize focal lung lesions. The previous study using
99mTc-EDDA/Hynic-octreotate (99mTc-EDDA/HYNIC-TATE) 
revealed higher tumor/lung ratios (8.3) than reported here 
(2.96,) and concluded that this analogue is an excellent alter-
native to 111In-Octreoscan for staging of carcinoids [15]. The
reason for a higher uptake of 99mTc-EDDA/HYNIC-TATE is 
its comparably higher potential to bind and internalize in 
tumor cells expressing SSTR2 than 99mTc-EDDA/HYNIC-
TOC [18]. 
The ﬁnal ﬁnding of our study is that intensity of tracer
uptake (T/NT ratio) in NETs is not closely associated with 
the rate of tumor proliferation (Ki-67 index). This result, how-
ever, has to be taken with caution considering a small sample 
size (n=11) available for correlation analysis. It is reassuring, 
however, that the relationship between 99mTc-EDDA/HYNIC-
TOC uptake and tumor proliferation rate was negative. The
negative correlation is expected because somatostatin recep-
tors responsible for tracer uptake are more expressed in slowly 
growing, highly diﬀerentiated NETs compared to aggressive
low-diﬀerentiated NETs [2, 5]. Therefore, a smaller uptake of
99mTc-EDDA/HYNIC-TOC is expected in NETs with a high 
proliferation rate. This is further supported by the ﬁnding
that two patients with low-diﬀerentiated NETs of high pro-
liferation rate were false negative on scintigraphy, as found 
in the previous report [19]. Positron emission tomography 
(PET) with 18Fluor (18F) ﬂuorothymidine (18F-FLT), which is 
a marker of tumor cell proliferation, similarly yields no cor-
relation between 18F-FLT uptake and Ki-67 [20]. PET imaging 
with 18F- ﬂuoro-deoxy-glucose (18F-FDG) is highly accurate 
in diﬀerentiating malignant from benign solitary lung lesions
[13] and for detecting NETs in the lungs due to diﬀerent FDG
metabolism in malignant and benign cells [21]. More recently, 
PET using speciﬁc 68Gallium (68Ga) labeled somatostatin ana-
logue DOTA-D-Phe1-Tyr3-(DOTATOC) was found superior to 
18F-FDG for detecting NETs [22]. However, PET is expensive 
and not easily accessible. On the other hand, because of its 
higher spatial resolution compared to SPECT, PET may be 
Table 2. Tumor size for 5 false negative cases on99mTc-EDDA/HYNIC-TOC 
scintigraphy
Lung lesion Size (cm)
Low-diﬀerentiated primary lung NET 1.4
Low-diﬀerentiated primary lung NET 3.5
Lung metastases from a low-diﬀerentiated NET in the es-
ophagus
1.7
Lung lesion from NET of unknown origin 1.9
Lung lesion from NET of unknown origin 4.2
NET- neuroendocrine tumor
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helpful for detecting small NETs with low density of SSTRs 
for which the classic, conventional scintigraphy seems insuf-
ﬁcient [23].
Three patients with NETs received radionuclide therapy
with radiolabeled somatostatin analogue 90Yttrium (90Y) DOTA 
TATE because of its high potential to bind and internalize in 
tumor cells expressing SSTR2 [18]. Despite our mixed results, 
radionuclide therapy with radiolabeled somatostatin analogues 
warrants further investigations in a larger sample. Such an 
approach may become the therapy of choice for patients with 
metastatic or inoperable NET [24]. 
This study has several limitations. 99mTc-EDDA/HYNIC-
TOC is indicated for diagnosis of tumors that express mainly 
SSTR2, thus of limited value for tumors expressing other recep-
tor types. Another limitation is that we did not evaluate in-vitro 
somatostatin receptor status, which is planned in our future 
investigations. In this series, however, SSTR2 was evidently 
expressed in lung lesions in patients with NETs, resulting in 
high sensitivity of 99mTc-EDDA/HYNIC-TOC scintigraphy. 
The limited spatial resolution of SPECT is also of concern
in detection of small lesions. A newly introduced hybrid 
SPECT/CT system provides precise anatomical localization 
with overall better visualization of lung lesions and increases 
sensitivity and speciﬁcity of scintigraphic ﬁndings [25].
In conclusion, our results demonstrate the clinical utility 
of SPECT and whole body scintigraphy with 99mTc-EDDA/
HYNIC-TOC for diagnosing NET tissue within the lungs. 
Although the two methods yield identical sensitivity, SPECT 
is preferred over whole body scintigraphy as it provides better 
visualization of lung lesions. The intensity of tracer uptake,
however, does not closely relate to the proliferation rate of 
NETs. Overall, 99mTc-EDDA/HYNIC-TOC scintigraphy may 
be helpful for selecting and monitoring treatment options, 
particularly when radiolabeled somatostatin analogue therapy 
becomes widely available. 
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